This thesis deals with the synthesis of protein and composite protein-mineral microcapsules by the application of high-intensity ultrasound at the oil-water interface. While one system is stabilized by BSA molecules, the other system is stabilized by different nanoparticles modified with BSA. A comprehensive study of all synthesis stages as well as of resulting capsules were carried out and a plausible explanation of the capsule formation mechanism was proposed. During the formation of BSA microcapsules, the protein molecules adsorb firstly at the O/W interface and unfold there forming an interfacial network stabilized by hydrophobic interactions and hydrogen bonds between neighboring molecules. Simultaneously, the ultrasonic treatment causes the cross-linking of the BSA molecules via the formation of intermolecular disulfide bonds. In this thesis, the experimental evidences of ultrasonically induced cross-linking of the BSA in the shells of protein-based microcapsules are demonstrated. Therefore, the concept proposed many years ago by Suslick and co-workers is confirmed by experimental evidences for the first time. Moreover, a consistent mechanism for the formation of intermolecular disulfide bonds in capsule shells is proposed that is based on the redistribution of thiol and disulfide groups in BSA under the action of high-energy ultrasound. The formation of composite protein-mineral microcapsules loaded with three different oils and shells composed of nanoparticles was also successful. The nature of the loaded oil and the type of nanoparticles in the shell, had influence on size and shape of the microcapsules. The examination of the composite capsule revealed that the BSA molecules adsorbed on the nanoparticles surface in the capsule shell are not cross-linked by intermolecular disulfide bonds. Instead, a Pickering emulsion formation takes place. The surface modification of composite microcapsules through both pre-modification of main components and also the post-modification of the surface of ready composite microcapsules was successfully demonstrated. Additionally, the mechanical properties of protein and composite protein-mineral microcapsules were compared. The results showed that the protein microcapsules are more resistant to elastic deformation.

Type 2 diabetes (T2D) is a complex metabolic disease regulated by an interaction of genetic predisposition and environmental factors. To understand the genetic contribution in the development of diabetes, mice varying in their disease susceptibility were crossed with the obese and diabetes-prone New Zealand obese (NZO) mouse. Subsequent whole-genome sequence scans revealed one major quantitative trait loci (QTL),Nidd/DBAon chromosome 4, linked to elevated blood glucose and reduced plasma insulin and low levels of pancreatic insulin. Phenotypical characterization of congenic mice carrying 13.6 Mbp of the critical fragment of DBA mice displayed severe hyperglycemia and impaired glucose clearance at week 10, decreased glucose response in week 13, and loss of beta-cells and pancreatic insulin in week 16. To identify the responsible gene variant(s), further congenic mice were generated and phenotyped, which resulted in a fragment of 3.3 Mbp that was sufficient to induce hyperglycemia. By combining transcriptome analysis and haplotype mapping, the number of putative responsible variant(s) was narrowed from initial 284 to 18 genes, including gene models and non-coding RNAs. Consideration of haplotype blocks reduced the number of candidate genes to four (Kti12,Osbpl9,Ttc39a, andCalr4) as potential T2D candidates as they display a differential expression in pancreatic islets and/or sequence variation. In conclusion, the integration of comparative analysis of multiple inbred populations such as haplotype mapping, transcriptomics, and sequence data substantially improved the mapping resolution of the diabetes QTLNidd/DBA. Future studies are necessary to understand the exact role of the different candidates in beta-cell function and their contribution in maintaining glycemic control.

In order to improve a recently established cell-based assay to assess the potency of botulinum neurotoxin, neuroblastoma-derived SiMa cells and induced pluripotent stem-cells (iPSC) were modified to incorporate the coding sequence of a reporter luciferase into a genetic safe harbor utilizing CRISPR/Cas9. A novel method, the double-control quantitative copy number PCR (dc-qcnPCR), was developed to detect off-target integrations of donor DNA. The donor DNA insertion success rate and targeted insertion success rate were analyzed in clones of each cell type. The dc-qcnPCR reliably quantified the copy number in both cell lines. The probability of incorrect donor DNA integration was significantly increased in SiMa cells in comparison to the iPSCs. This can possibly be explained by the lower bundled relative gene expression of a number of double-strand repair genes (BRCA1, DNA2, EXO1, MCPH1, MRE11, and RAD51) in SiMa clones than in iPSC clones. The dc-qcnPCR offers an efficient and cost-effective method to detect off-target CRISPR/Cas9-induced donor DNA integrations.

The role of the GMP nucleotides of the bis-molybdopterin guanine dinucleotide (bis-MGD) cofactor of the DMSO reductase family has long been a subject of discussion. The recent characterization of the bis-molybdopterin (bis-Mo-MPT) cofactor present in the E. coli YdhV protein, which differs from bis-MGD solely by the absence of the nucleotides, now enables studying the role of the nucleotides of bis-MGD and bis-MPT cofactors in Moco insertion and the activity of molybdoenzymes in direct comparison. Using the well-known E. coli TMAO reductase TorA as a model enzyme for cofactor insertion, we were able to show that the GMP nucleotides of bis-MGD are crucial for the insertion of the bis-MGD cofactor into apo-TorA.

microRNAs (miRNAs) have been identified as high-value drug targets. A widely applied strategy in miRNA inhibition is the use of antisense agents. However, it has been shown that oligonucleotides are poorly cell permeable because of their complex chemical structure and due to their negatively charged backbone. Consequently, the general application of oligonucleotides in therapy is limited. Since miRNAs’ functions are executed exclusively by the Argonaute 2 protein, we therefore describe a protocol for the design of a novel miRNA inhibitor class: antagonists of the miRNA-Argonaute 2 protein complex, so-called anti-miR-AGOs, that not only block the crucial binding site of the target miRNA but also bind to the protein’s active site. Due to their lower molecular weight and, thus, more drug-like chemical structure, the novel inhibitor class may show better pharmacokinetic properties than reported oligonucleotide inhibitors, enabling them for potential therapeutic use.